The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

Welcome to The Native Antigen Company

Critical Reagents for Human Health

Antigens and Antibodies

 

We specialise in the development and manufacture of antigens and antibodies for viral and bacterial pathogens. We produce both native and recombinant antigens using our a range of cell expression systems and have decades of experience in bulk and scale production.

Contract Production and Assay Services

 

We can undertake custom projects to manufacture antigens and other proteins, prepare antibodies and develop immunoassays to support your R&D. Our development laboratories are staffed by a team of PhD molecular biologists and development scientists who are able to execute projects as short as a few days, through to long-term programmes of a year or more.

Omicron variant

Omicron Variant Antigens Now Available

The Native Antigen Company now offers whole Spike, S1 and RBD antigens for the SARS-CoV-2 Omicron (B.1.1.529) variant.

Norovirus 3D model

Monkey Pox

A series of antigens to support research into this disease are under development at The Native Antigen Company.

Virology testing services

New Virology Testing Services Available

The Native Antigen Company now offers a range of capabilities for virological research and the development of viral diagnostics, therapeutics, and vaccines.

About The Native Antigen Company

The Native Antigen Company develops and manufactures premium quality antigens and antibodies as well as offering a range of services to the diagnostic and biopharmaceutical industries.

Our proprietary VirtuE™ expression system has been developed for the purpose of producing native-like proteins, which are widely adopted by leading in vitro diagnostic, vaccine and academic groups in cutting-edge R&D, where correct folding and glycosylation are vital. Our contract services range from antibody generation, to scale production of recombinant and native antigens, and bespoke assay development and QC.

Building on our recognised expertise in infectious diseases, we are expanding our portfolio to include a range of disease-state markers and other critical reagents for human health.

Monkeypox; 3 months on

It has been 3 months since a new, unusually widespread outbreak of Monkeypox was first identified. What was normally a virus confined to limited infections in the West African continent is becoming a global health concern.   What have we learned about this virus...

COVID-19 Underlines the Need for Universal Vaccines

This article was originally published on Clinical Lab Manager. In recent history, humanity has witnessed numerous emerging viral diseases, including the SARS, MERS, and SARS-2 coronaviruses, as well as HIV, Zika, Ebola, and H1N1 and H3N2 influenza. None have tested...

Tick-Borne Diseases: The Need for Integrated Approaches to Human-Animal Diagnosis

This article has been published in Volume 8, Issue 3 of International Animal Health Journal. Ticks are responsible for a diverse group of neglected, and rapidly expanding diseases, affecting humans, companion animals and livestock. A growing understanding of tick-host...

The Continued Challenges of Flavivirus Serology

This article was originally published on the Science Advisory Board. Flaviviruses are a genus of positive-sense RNA viruses, largely transmitted by mosquito and tick vectors that cause infections, including yellow fever, dengue, the Zika virus, West Nile virus,...

The Role of Serology in Tracking COVID-19 Mutations

This article was originally published on Clinical Lab Products. As SARS-CoV-2 began its global proliferation in early 2020, scientists hastened to investigate its biology, develop diagnostic tests, and design candidate vaccines, marking one of the most...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

13 + 3 =